RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov
; 13(9): 2012-2031, 2023 09 06.
Article
in En
| MEDLINE
| ID: mdl-37270847
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Bile Duct Neoplasms
/
Cholangiocarcinoma
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Cancer Discov
Year:
2023
Type:
Article